UCB SA (OTCMKTS:UCBJF – Get Free Report) shares saw unusually-high trading volume on Monday. 3,864 shares changed hands during trading, an increase of 493% from the average daily volume of 652 shares. The stock last traded at $313.8125 and had previously closed at $317.34.
Wall Street Analyst Weigh In
Several equities research analysts have commented on UCBJF shares. Stephens restated an “overweight” rating on shares of UCB in a research note on Wednesday, October 21st. Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Finally, Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a report on Monday, August 3rd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.
UCB Stock Performance
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business’s 50 day simple moving average is $254.23 and its 200-day simple moving average is $285.79.
About UCB
UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.
The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).
Featured Articles
- Five stocks we like better than UCB
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
